Cargando…

Metronomic Capecitabine in Patients With Hepatocellular Carcinoma Unresponsive to or Ineligible for Sorafenib Treatment: Report of Two Cases

INTRODUCTION: Sorafenib, an oral multikinase inhibitor, is the only systemic agent proven to be effective in patients with hepatocellular carcinoma (HCC). There are no approved second line systemic therapies in patients who have had disease progression on or are not eligible to sorafenib. CASE PRESE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marinelli, Sara, Granito, Alessandro, Piscaglia, Fabio, Renzulli, Matteo, Stagni, Angela, Bolondi, Luigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kowsar 2013
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830515/ https://www.ncbi.nlm.nih.gov/pubmed/24282421 http://dx.doi.org/10.5812/hepatmon.11721

Ejemplares similares

Experience with regorafenib in the treatment of hepatocellular carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021)

Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC
por: Granito, Alessandro, et al.
Publicado: (2021)

TACE performed in patients with a single nodule of Hepatocellular Carcinoma
por: Terzi, Eleonora, et al.
Publicado: (2014)

Medical Treatment of Hepatocellular Carcinoma
por: Granito, Alessandro, et al.
Publicado: (2009)

The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation
por: Ravaioli, Matteo, et al.
Publicado: (2017)

Beneficial Prognostic Effects of Aspirin in Patients Receiving Sorafenib for Hepatocellular Carcinoma: A Tale of Multiple Confounders
por: Ielasi, Luca, et al.
Publicado: (2021)

Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma
por: Ielasi, Luca, et al.
Publicado: (2023)

Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma?
por: Kim, Do Young
Publicado: (2017)

COVID-19: Has the Liver Been Spared?
por: Brandi, Nicolò, et al.
Publicado: (2023)

Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib
por: Sansone, Vito, et al.
Publicado: (2021)

Very Low Alcohol Consumption Is Associated with Lower Prevalence of Cirrhosis and Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease
por: Ferri, Silvia, et al.
Publicado: (2022)

Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases
por: Brandi, Giovanni, et al.
Publicado: (2018)

Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept
por: De Lorenzo, Stefania, et al.
Publicado: (2018)

Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma
por: Al-Sukhun, Sana, et al.
Publicado: (2023)

Hepatocellular adenoma: An unsolved diagnostic enigma
por: Renzulli, Matteo, et al.
Publicado: (2019)

TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021)

The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib
por: Caputo, Francesco, et al.
Publicado: (2020)

Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature
por: Bongiovanni, Alberto, et al.
Publicado: (2014)

Metronomic chemotherapy with capecitabine for metastatic colorectal cancer in very elderly patients
por: Jung, Yun Hwa, et al.
Publicado: (2017)

Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study
por: Casadei Gardini, Andrea, et al.
Publicado: (2017)

Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments
por: Suzuki, Hiroyuki, et al.
Publicado: (2021)

Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma
por: Marinelli, Sara, et al.
Publicado: (2014)

MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma
por: Turato, Cristian, et al.
Publicado: (2019)

Cost-effectiveness analysis of metronomic capecitabine as adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma
por: She, Longjiang, et al.
Publicado: (2022)

Metronomic capecitabine inhibits liver transplant rejection in rats by triggering recipients’ T cell ferroptosis
por: Wang, Hao, et al.
Publicado: (2023)

Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08‐20
por: Patt, Yehuda, et al.
Publicado: (2017)

Treatment of Combined Hepatocellular and Cholangiocarcinoma
por: Leoni, Simona, et al.
Publicado: (2020)

Segmental Distribution of Hepatocellular Carcinoma in Cirrhotic Livers
por: Renzulli, Matteo, et al.
Publicado: (2022)

Pathobiological and Radiological Approach For Hepatocellular Carcinoma Subclassification
por: Vasuri, Francesco, et al.
Publicado: (2019)

Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study
por: Berruti, Alfredo, et al.
Publicado: (2014)

Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second‐line clinical trials
por: Tovoli, Francesco, et al.
Publicado: (2021)

The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma
por: Pollutri, Daniela, et al.
Publicado: (2018)

Metronomic capecitabine as maintenance treatment after first line induction with XELOX for metastatic colorectal cancer patients
por: Geng, Rui, et al.
Publicado: (2020)

A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function
por: Yang, Hyun, et al.
Publicado: (2017)

Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review
por: Maur, Michela, et al.
Publicado: (2017)

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study
por: Pietrantonio, Filippo, et al.
Publicado: (2016)

Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions
por: Fornari, Francesca, et al.
Publicado: (2021)

The Feasibility of Liver Biopsy for Undefined Nodules in Patients under Surveillance for Hepatocellular Carcinoma: Is Biopsy Really a Useful Tool?
por: Renzulli, Matteo, et al.
Publicado: (2022)

A systematic review on the available treatment modalities for Bacillus Calmette–Guérin-unresponsive carcinoma in situ and tumors in patients who are ineligible for or decline radical cystectomy
por: Syed, Saad, et al.
Publicado: (2023)

Prognosis of Single Early-Stage Hepatocellular Carcinoma (HCC) with CEUS Inconclusive Imaging (LI-RADS LR-3 and LR-4) Is No Better than Typical HCC (LR-5)
por: Terzi, Eleonora, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_eu4ggef1nnlmds25ael2ihcaou